Skip to main content
Canna~Fangled Abstracts

Cannabidiol Increases Seizure Resistance and Improves Behavior in an Scn8a Mouse Model

By January 26, 2022February 15th, 2022No Comments
. 2022 Jan 26;13:815950.

doi: 10.3389/fphar.2022.815950. eCollection 2022.

Lindsey Shapiro 1, Andrew Escayg 1, Jennifer C Wong 1
Affiliations 

Free PMC article

Abstract

Voltage-gated sodium channel genes are an important family of human epilepsy genes. De novo missense mutations in SCN8A (encoding Nav1.6) are associated with a spectrum of clinical presentation, including multiple seizure types, movement disorders, intellectual disability, and behavioral abnormalities such as autism. Patients with SCN8A mutations are often treated with multiple antiepileptic drugs, the most common being sodium channel blockers. Cannabidiol (CBD) has been included as a component of treatment regimens for some SCN8A patients; however, to date, there are no clinical trials that have evaluated the therapeutic potential of CBD in patients with SCN8A mutations. In the current manuscript, we demonstrated a dose-dependent increase in seizure resistance following CBD treatment in mice expressing the human SCN8A mutation R1620L (RL/+). We also found that CBD treatment improved social behavior and reduced hyperactivity in the RL/+ mutants. Our findings suggest that CBD may be beneficial in patients with SCN8A-associated disease.

Keywords: SCN8A, behavior, epilepsy, mouse, seizure, sodium channel

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1

FIGURE 2

FIGURE 3

References

    1. Anderson L. L., Low I. K., McGregor I. S., Arnold J. C. (2020). Interactions between Cannabidiol and Δ9 -tetrahydrocannabinol in Modulating Seizure Susceptibility and Survival in a Mouse Model of Dravet Syndrome. Br. J. Pharmacol. 177, 4261–4274. 10.1111/bph.15181 – DOI – PMC – PubMed
    1. Aran A., Harel M., Cassuto H., Polyansky L., Schnapp A., Wattad N., et al. (2021). Cannabinoid Treatment for Autism: A Proof-Of-Concept Randomized Trial. Mol. Autism 12, 6. 10.1186/s13229-021-00420-2 – DOI – PMC – PubMed
    1. Barton M. E., Klein B. D., Wolf H. H., White H. S. (2001). Pharmacological Characterization of the 6 Hz Psychomotor Seizure Model of Partial Epilepsy. Epilepsy Res. 47, 217–227. 10.1016/s0920-1211(01)00302-3 – DOI – PubMed
    1. Butler K. M., da Silva C., Shafir Y., Weisfeld-Adams J. D., Alexander J. J., Hegde M., et al. (2017). De Novo and Inherited SCN8A Epilepsy Mutations Detected by Gene Panel Analysis. Epilepsy Res. 129, 17–25. 10.1016/j.eplepsyres.2016.11.002 – DOI – PMC – PubMed
    1. Campos A. C., Guimarães F. S. (2008). Involvement of 5HT1A Receptors in the Anxiolytic-like Effects of Cannabidiol Injected into the Dorsolateral Periaqueductal gray of Rats. Psychopharmacology (Berl) 199, 223–230. 10.1007/s00213-008-1168-x – DOI – PubMed

LinkOut – more resources

Leave a Reply